Prescription treatments for erectile dysfunction have entered a new phase. Instead of offering only standard tablets such as sildenafil or tadalafil, online men’s-health companies now market rapidly dissolving tablets, mints, gummies, liquids, and “custom” combinations containing two, three, or four active ingredients.
The appeal is easy to understand. Sildenafil and tadalafil work primarily by increasing blood flow to the penis. Other ingredients are promoted as acting on sexual desire, arousal, intimacy, or the brain’s response to sexual stimulation. The marketing message is that combining these ingredients may produce a faster, firmer, more reliable erection.
The major products include BlueChew GOLD, Rugiet Ready, Ro Sparks, and MEDVi QUAD. But there is an important distinction: these products do not all contain four ingredients. BlueChew GOLD and MEDVi QUAD are marketed as four-ingredient treatments. Rugiet Ready contains three active ingredients, while Ro Sparks contains two.
The central question is not whether the individual medications can work. Several of them clearly can. The more difficult question is whether combining them produces better results than a single, properly selected medication. At present, there is little clinical evidence to support that claim.
What is in these products?
BlueChew GOLD is advertised as a compounded sublingual tablet containing sildenafil, tadalafil, apomorphine, and oxytocin. The company describes the first two ingredients as supporting erectile firmness, apomorphine as supporting sexual arousal, and oxytocin as supporting intimacy and sexual connection.
Rugiet Ready contains sildenafil, tadalafil, and apomorphine. It is marketed as a treatment that addresses both the “brain” and the “body”—using sildenafil and tadalafil to support blood flow and apomorphine to promote the central arousal signal. Rugiet describes the product as a fast-dissolving treatment and has promoted it as an option to try before considering penile injections such as Trimix.
Ro Sparks is a compounded two-in-one treatment containing sildenafil and tadalafil. It is designed as a sublingual product and is advertised as combining sildenafil’s relatively rapid action with tadalafil’s longer duration. Ro has promoted the product as beginning to work in approximately 15 minutes and lasting as long as 36 hours, although individual response varies.
MEDVi QUAD is more difficult to evaluate because public descriptions of its formulation have changed. Earlier materials described a combination of sildenafil, tadalafil, vardenafil, and apomorphine. More recent descriptions have identified sildenafil, tadalafil, apomorphine, and L-citrulline, while other 2026 reports have described a version containing PT-141 and L-citrulline instead of vardenafil and apomorphine. Anyone considering the product should verify the exact ingredients and doses on the prescription label.
This shifting formulation is not a minor detail. The evidence, possible side effects, and drug interactions depend on the exact ingredients and amounts.
The strongest evidence: sildenafil and tadalafil
Sildenafil and tadalafil are the best-established ingredients in these products. Both are phosphodiesterase-5, or PDE-5, inhibitors. They enhance the body’s natural erectile response by helping preserve the chemical signal that relaxes smooth muscle and increases blood flow in the penis.
Both drugs have been studied extensively in randomized clinical trials and are FDA-approved for erectile dysfunction. Sildenafil generally begins working within about 30 to 60 minutes and lasts for several hours. Tadalafil has a longer duration of action—often up to 36 hours—and can also be prescribed as a low-dose daily medication.
Neither drug automatically produces an erection. Sexual stimulation is still necessary. Their effectiveness also depends on dose, timing, food intake in the case of sildenafil, general health, cardiovascular status, and the underlying cause of the ED.
For many men, the most appropriate treatment is simply one of these medications, selected and prescribed correctly. The fact that a combination product contains sildenafil or tadalafil means that it contains a medication with strong evidence. It does not mean that the complete product has been shown to work better.
The less-established ingredients
The evidence is less solid for the additional ingredients.
Apomorphine acts on dopamine receptors in the brain and may help initiate the neural signals involved in sexual arousal. It has been studied for ED, but trials comparing apomorphine with sildenafil generally found sildenafil more effective or more frequently preferred. Apomorphine is not FDA-approved in the United States for ED; its U.S. approval is for Parkinson’s disease.
Oxytocin is a hormone associated with social bonding, sexual behavior, and intimacy. Those biological associations make it an appealing marketing ingredient, but evidence that sublingual oxytocin meaningfully improves erectile function in men is limited. A plausible role in intimacy is not the same as proof that it produces a harder or more reliable erection.
L-citrulline is an amino acid that can increase availability of L-arginine, which is involved in nitric-oxide production. Small studies suggest that L-citrulline or related supplements may modestly improve erectile function in some men. However, this evidence is much weaker than the evidence supporting sildenafil and tadalafil, and it does not demonstrate that the dose used in a particular compounded product adds a meaningful benefit.
PT-141, also known as bremelanotide, acts through melanocortin pathways involved in sexual desire and arousal. It is FDA-approved for acquired, generalized low sexual desire in certain premenopausal women, not for routine male ED. Its presence in a compounded male product therefore represents an off-label or non-approved use.
The difference between these ingredients matters. Marketing often places all four components on the same level, but the clinical evidence is not equal. Sildenafil and tadalafil have large bodies of evidence for male ED. Apomorphine has some evidence but is generally less established. Oxytocin, L-citrulline, and PT-141 have more limited or indirect evidence for this particular use.
Have the combinations been tested?
This is the most important weakness in the marketing claims.
There have been studies of some ED combination treatments. For example, research has examined tadalafil used regularly with sildenafil taken as needed in men who did not respond adequately to one drug. A systematic review has also suggested that combination therapy may help selected men with difficult-to-treat ED.
But those studies do not prove that BlueChew GOLD, Rugiet Ready, Ro Sparks, or MEDVi QUAD is superior to sildenafil or tadalafil alone. The branded products have their own doses, delivery systems, manufacturing processes, and ingredient combinations. Those exact formulations need to be tested in well-designed randomized trials.
So far, there is no convincing head-to-head evidence showing that these commercial combination products produce better erectile-function scores, higher intercourse-success rates, greater patient satisfaction, or better long-term outcomes than a properly used single PDE-5 inhibitor.
A sublingual tablet may feel faster than a swallowed tablet for some people, but faster perceived onset is not the same as greater overall effectiveness. Nor does the presence of more active ingredients necessarily create a stronger or more reliable response.
What about claims that they are “as good as Trimix”?
Trimix is a very different treatment. It is an injectable compounded medication typically containing alprostadil, papaverine, and phentolamine. The medication is injected directly into the penis and acts locally to produce an erection. It is often used when oral medications fail or cannot be used.
Some companies position their combination products as alternatives to, or treatments to try before, penile injections. That is a reasonable marketing position if it is presented as an option. It becomes misleading if it implies that the products have been proven equivalent to Trimix.
To establish that a sublingual combination is “as good as Trimix,” researchers would need to conduct a direct comparative trial using clinically meaningful outcomes. That would include erection hardness, successful intercourse, patient preference, adverse effects, and durability of benefit.
The existence of effective ingredients in both treatments is not enough. Sildenafil and tadalafil are not pharmacologically equivalent to an intracavernosal injection. A company’s claim that a product is “as good as Trimix” should therefore be treated as a promotional claim unless supported by head-to-head clinical evidence.
What do these products cost?
Combination products are generally more expensive per dose than generic single-ingredient medications, although the exact comparison depends on the dose, quantity, subscription plan, consultation fee, shipping charge, and promotional discount.
BlueChew has advertised GOLD at approximately $7.30 to $18.28 per dose, depending on strength and purchasing plan. Ro has advertised Sparks at about $12 per dose on a monthly plan. Rugiet’s price varies by dose and quantity, with some company materials describing prices around $10 or more per dose. MEDVi has advertised QUAD at approximately $114 per month, although the number of included doses and the current formulation should be verified before calculating a per-dose price.
By comparison, generic sildenafil and tadalafil obtained through a conventional pharmacy or discount service may cost $1 to $4 per dose. Prices vary widely by pharmacy and dosage, but GoodRx lists generic tadalafil and sildenafil among the lower-cost prescription options when coupons are used.
A fair price comparison should therefore use the actual cash price per dose after discounts, not a manufacturer’s crossed-out reference price. It should also identify whether the price includes the medical consultation, prescription, shipping, refills, and customer support.
Customers may reasonably decide that privacy, convenience, a fast online consultation, or a dissolving tablet is worth paying for. A higher price does not by itself indicate that a product is a bad value. It does mean, however, that buyers should not assume they are paying for a clinically proven increase in effectiveness.
The bottom line
Custom ED formulations combine medications with very different levels of evidence. Sildenafil and tadalafil are well-supported treatments for male ED. Apomorphine, oxytocin, L-citrulline, and PT-141 may have plausible roles in selected patients, but the evidence is more limited and less directly applicable.
Most importantly, the exact commercial combinations have not been adequately tested against single-ingredient sildenafil or tadalafil. There is no convincing clinical evidence that adding more ingredients produces better erections for the average patient.
These products may offer convenience and may help some men who have not responded adequately to a standard medication. But claims that they are “stronger,” “more reliable,” or “as good as Trimix” should be viewed as marketing claims unless supported by direct clinical comparisons.
For consumers, the essential questions are straightforward: What exactly is in the product? At what dose? What evidence supports each ingredient? Has the complete combination been tested? What does it cost per dose? And is the product being compared fairly with an appropriately prescribed generic medication?
At present, the strongest evidence supports choosing the simplest effective treatment—not necessarily the product with the most ingredients.